Natera Inc. (NASDAQ:NTRA) shares are soaring up +20% this morning after the healthcare company released its Q4 and full 2018 earnings. The healthcare stock is seeing its biggest share rise today in well over six months. Investors seem pleased with Natera’s earnings, so if you’ve been looking for a healthcare stock to add to your portfolio, NTRA may be one to keep your eye on!
Natera Sees 23% Growth in Revenue in 2018
Natera Inc. generated $257.7 million in total revenue for the full year in 2018, representing a +23% growth over its 2017 revenue. The company processed over 668,000 tests for the full year of 2018, an increase of +30% from the previous year. In Q4 2018, Natera Inc. generated $67 million in growth and processed 174,200 tests.
Natera is a genetic testing company that develops and commercializes non-invasive methods of analyzing DNA. A large portion of the tests performed by the company are preconception and prenatal genetic testing, which bring in most of Natera’s annual revenue. Prenatal and preconception testing isn’t the only testing Natera performs and in the press release today the healthcare company highlighted its advancements in other fields of medicine.
Two months ago, Natera announced the publication of a kidney transplant validation study that was published in the Journal of Clinical Medicine. This study demonstrated the high accuracy in its donor-derived cell-free DNA test for active allograft rejection in kidney transplant patients. The healthcare stock also offers tests in the field of oncology.
>> Penny Stocks in Healthcare: DarioHealth Could Soar
Steve Chapman, Natera’s CEO, explained:
“We grew revenues substantially over 2017, doubled our volume growth rate year over year, and delivered compelling data in both oncology and in kidney transplant rejection. We see 2019 as a key inflection point for Natera across reproductive health, oncology, and transplant.”
Healthcare Stock Movement
According to Yahoo Finance, NTRA is trading at $20.05 a share, up +$3.39 (+20.35%). Natera Inc. has shown promising results in the fields of diagnostics and research, and an impressive revenue growth in 2018. What do you think about this healthcare stock?
Featured Image: Unsplash
